Skip to content
  • Wednesday, 28 October 2026
  • 1:38 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Pharmaceutical R&D

Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline

Teuku Ryan Apr 8, 2026 0

Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…

Read More
Pharmaceutical R&D

RoosterBio and MineBio Forge Exclusive Partnership to Accelerate MSC and Exosome Therapies in China

Teuku Ryan Apr 8, 2026 0

RoosterBio, a prominent innovator in the field of mesenchymal stem cell (MSC) and exosome bioprocessing, has announced an exclusive distributor…

Read More
Pharmaceutical R&D

The Hyper-Connected Hospital: Bridging the Gap Between Digital Ambition and Network Readiness

Teuku Ryan Apr 8, 2026 0

The healthcare landscape is undergoing a profound metamorphosis, transforming hospitals into hyper-connected environments where artificial intelligence applications, remote patient monitoring,…

Read More
Pharmaceutical R&D

US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs

Teuku Ryan Apr 8, 2026 0

The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…

Read More
Pharmaceutical R&D

Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline

Teuku Ryan Apr 7, 2026 0

Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…

Read More
Pharmaceutical R&D

Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109

Teuku Ryan Apr 7, 2026 0

Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…

Read More
Pharmaceutical R&D

European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer

Teuku Ryan Apr 6, 2026 0

The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…

Read More
Pharmaceutical R&D

Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases

Teuku Ryan Apr 6, 2026 0

Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…

Read More
Pharmaceutical R&D

Biocytogen and Sihuan Pharmaceutical Forge Strategic Alliance to Accelerate Advanced Therapies, Including Novel Weight Loss Treatments

Teuku Ryan Apr 3, 2026 0

The pharmaceutical landscape is poised for significant advancement as Biocytogen, a leader in antibody-based drug discovery, and Sihuan Pharmaceutical, a…

Read More
Pharmaceutical R&D

Merck KGaA Acquires JSR Life Sciences’ Chromatography Business to Bolster Biopharmaceutical Purification Capabilities

Teuku Ryan Apr 3, 2026 0

Germany-based Merck KGaA, a leading science and technology company, has officially completed its previously announced acquisition of the chromatography business…

Read More

Posts pagination

1 … 36 37 38 … 43
SmolVLM2-2.2B Revolutionizes Local Video Summarization with Consumer Hardware AccessibilityShionogi Expands Rare Disease Portfolio With $2 Billion Acquisition of IntraBio and Flagship Drug AqneursaNew Brain Circuitry Discovery Offers Potential Breakthrough for Treating Chronic Neuropathic PainUnlocking Bacterial Mobility: New Research Reveals Novel Swarming and Gear-Shifting Mechanisms Crucial for Infection Control
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
The oral exposure challenge in PROTACs: What drug developers need to solve earlyThe Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALSESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial CancerThe Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Oct 28, 2026
Environmental & Analytical Chemistry
The Silence Broken: How Brain-Computer Interfaces are Restoring the Human Voice for Those Paralyzed by ALS
Abdurrohim Arsyad Oct 28, 2026
Pharmaceutical R&D
ESMO26: KEYNOTE-C93 Backs Chemo-Free Keytruda in dMMR Endometrial Cancer
Teuku Ryan Oct 28, 2026
Molecular & Cell Biology
The Discovery of REM-like Sleep in Jumping Spiders Challenges Traditional Views of Animal Consciousness
Angie Faith Oct 28, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ